Ectasia Clinical Trials

34 recruitingLast updated: July 25, 2026

There are 34 actively recruiting ectasia clinical trials across 20 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4. Top locations include Boston, Massachusetts, United States, Rochester, Minnesota, United States, Indianapolis, Indiana, United States. Updated daily from ClinicalTrials.gov.


Ectasia Trials at a Glance

34 actively recruiting trials for ectasia are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Boston, Rochester, and Indianapolis. Lead sponsors running ectasia studies include Hospital Italiano de Buenos Aires, Imperial College London, and Mayo Clinic.

Browse ectasia trials by phase

Treatments under study

About Ectasia Clinical Trials

Looking for clinical trials for Ectasia? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ectasia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ectasia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Gastrointestinal BleedingTelangiectasiaArteriovenous Malformations+4 more
Cure HHT10,000 enrolled16 locationsNCT06259292
Recruiting
Phase 1Phase 2

DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia

Pulmonary Arterial HypertensionHereditary hemorrhagic telangiectasia
Diagonal Therapeutics, Inc.93 enrolled5 locationsNCT07623525
Recruiting
Not Applicable

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

Rendu Osler DiseaseHereditary hemorrhagic telangiectasia
University Hospital, Clermont-Ferrand100 enrolled18 locationsNCT05641142
Recruiting
Not Applicable

Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique

SclerotherapyNd:YAG LaserDiode Laser+3 more
Ain Shams University80 enrolled1 locationNCT07678697
Recruiting
Phase 1

Topical TOR-582 Treatment of Epistaxis in HHT

EpistaxisHereditary Hemorrhagic Telangiectasia (HHT)
Columbia University27 enrolled1 locationNCT07667413
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary hemorrhagic telangiectasia
Alnylam Pharmaceuticals120 enrolled16 locationsNCT06659640
Recruiting

Corneal Elastography and Patient Specific Modeling

KeratoconusCornea; EctasiaRefractive errors
The Cleveland Clinic60 enrolled1 locationNCT03030755
Recruiting
Phase 4

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals285 enrolled26 locationsNCT06971939
Recruiting
Phase 1Phase 2

Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)

Ataxia-telangiectasia
Timothy Yu10 enrolled1 locationNCT07215416
Recruiting
Phase 4

Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia

Coronary Artery EctasiaSTEMI - ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)+1 more
Instituto Nacional de Cardiologia Ignacio Chavez326 enrolled1 locationNCT07511257
Recruiting
Not Applicable

Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)

Gastric Antral Vascular Ectasia
Mayo Clinic50 enrolled1 locationNCT07169799
Recruiting
Phase 2

Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients

Telangiectasia, Hereditary Hemorrhagic
Dr. Romain Lazor48 enrolled3 locationsNCT04976036
Recruiting

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

CirrhosisChronic Kidney DiseaseGastric Antral Vascular Ectasia
Mayo Clinic30 enrolled1 locationNCT06306963
Recruiting
Phase 1

A single ascending dose study of TX002100 in healthy participants

Hereditary hemorrhagic telangiectasia
Tectonic Operating Company. Inc.48 enrolled1 locationACTRN12626000242325
Recruiting
Not Applicable

Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device

Hereditary Haemorrhagic TelangiectasiaPulmonary Arteriovenous MalformationPFO - Patent Foramen Ovale
St. Antonius Hospital40 enrolled1 locationNCT07414446
Recruiting
Phase 3

Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases

KeratoconusEctasia of CorneaPellucid Marginal Corneal Degeneration+1 more
Woolfson Eye Institute485 enrolled12 locationsNCT07124910
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting
Phase 1

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia (HHT)
Terremoto Biosciences Inc.90 enrolled1 locationNCT07255846
Recruiting

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

KeratoconusFuchs' Endothelial DystrophyEctasia+1 more
Massachusetts General Hospital168 enrolled1 locationNCT02118922
Recruiting
Phase 2

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

Corneal EctasiaKeratoconusPellucid Marginal Corneal Degeneration
Goodman Eye Center500 enrolled1 locationNCT04094090